Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0802 • ACR Convergence 2021
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Laval University, Québec City, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Providence Health Care, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montreal, ON, Canada
Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
Abstract Number: 0820 • ACR Convergence 2021
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1066 • ACR Convergence 2021
Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
Pedro Santos-Moreno¹, Rosangela Casanova², Gabriel-Santiago Rodríguez-Vargas², Laura Villareal¹, Jaime-Andrés Rubio², Josefina Chávez-Chávez², Diana Patricia Rivera-Triana², Ruth Alexandra Castiblanco-Montañez², Sandra Milena Hernández-Zambrano² and Adriana Rojas-Villarraga², ¹BIOMAB IPS, Bogotá, Colombia, ²Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
Background/Purpose: The COVID-19 pandemic impacted everyday practice pattern of health care in rheumatoid arthritis (RA) patients. The objective was to evaluate the implementation of a…
Abstract Number: 1197 • ACR Convergence 2021
Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
Adelina Plachokova¹, Jill Hadisurya¹, Julia van Bergen² and Rogier Thurlings³, ¹Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, Netherlands, ²Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, ³Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Transversal cohort studies demonstrated a possible association between periodontal disease (PD) and rheumatoid arthritis (RA). However it is unknown how this association evolves during…
Abstract Number: 1213 • ACR Convergence 2021
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
Christoph Baerwald¹, Edgar Stemmler², Sixten Gnuechtel², Katharina Birkner², Carsten Holland³, Bjoern Fritz², Daniela Adolf⁴ and Ralf Baron⁵, ¹University Hospital Leipzig, Leipzig, Germany, ²AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ³AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁴StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁵University Hospital Schleswig-Holstein, Kiel, Germany
Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
Abstract Number: 1229 • ACR Convergence 2021
Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Rieke Alten¹, Xavier Mariette², Melanie Chartier³, Christiane Rauch⁴, Yedid Elbez⁵, Karissa Lozenski⁶ and Vadim Khaychuk⁶, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Bristol Myers Squibb, Rueil-Malmaison, France, ⁴Bristol Myers Squibb, Munich, Germany, ⁵Deepscover, Puteaux, France, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: BMI has been shown to affect treatment response and may influence the development of optimal individualized treatment plans in patients with RA.1 The extent…
Abstract Number: 1245 • ACR Convergence 2021
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
Cecile PHILIPPOTEAUX¹, Valentine DEPREZ², Jean-Guillaume LETAROUILLY¹, Emeline CAILLIAU³, Eric HOUVENAGEL⁴, Xavier DEPREZ⁵, Aurore NOTTEZ⁶, Peggy PHILIPPE¹, Tristan PASCART⁷, Vincent GOEB² and Rene-Marc FLIPO⁸, ¹Rheumatology Department, University Hospital of Lille, Lille, France, ²Rheumatology Department, University Hospital of Amiens, Amiens, France, ³Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, ⁴Rheumatology Department, Lille Catholic Hospitals, Lomme, France, ⁵Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, ⁶Rheumatology Department, University Hospital of Dunkerque, Dunkerque, France, ⁷Department of Rheumatology, Lille Catholic Hospitals, Lomme, France, ⁸Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: In recent decades, the therapeutic arsenal in RA has dramatically expanded. Baricitinib (BARI) and Tofacitinib (TOFA) were the first JAK inhibitors (JAKi) to be…
Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Manuel Pombo-Suarez¹, Carlos Sanchez-Piedra², Juan J Gomez-Reino³, Kim Lauper⁴, Nevsun Inanc⁵, Anja Strangfeld⁶, Doreen Huschek⁷, Karel Pavelka⁸, Eirik Kristianslund⁹, Tore Kvien¹⁰, Ziga Rotar¹¹, Dan Nordström¹², Denis Choquette¹³, Ori Elkayam¹⁴, Burkhard Leeb¹⁵, Maria José Santos¹⁶, Kimme Hyrich¹⁷, Lianne Kearsley-Fleet¹⁸, Catalin Codreanu¹⁹, Denis Monguin²⁰, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁴Geneva University Hospitals, Geneve, Switzerland, ⁵Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹²Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ¹³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ¹⁴Tel Aviv Medical Center, Tel Aviv, Israel, ¹⁵Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, ¹⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁹Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²⁰Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²¹University Hospital of Geneva, Geneve - Vesenaz, Switzerland
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1660 • ACR Convergence 2021
Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
So Hye Nam¹, Min-Ju Kim², Ye-Jee kim², Soo Min Ahn², Seokchan Hong³, Chang-Keun Lee², Bin Yoo³, Ji Seon Oh⁴ and Yong-Gil Kim², ¹Uijeongbu Eulji Medical Center, Uijeongbu, Gyeonggi-do, Republic of Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Seoul, South Korea, ⁴Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects glucose metabolism, mainly insulin resistance, which can lead to diabetes mellitus (DM). Although there…
Abstract Number: 1676 • ACR Convergence 2021
Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice
Takao Fujii¹, Tatsuya Atsumi², Nami Okamoto³, Nobunori Takahashi⁴, Naoto Tamura⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Hiroaki Matsuno⁸, Naoto Tsujimoto⁹, Atsushi Nishikawa¹⁰, Taeko Ishii¹⁰, Tsutomu Takeuchi¹¹, Masataka Kuwana¹² and Michiaki Takagi¹³, ¹Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ²Hokkaido University, Sapporo, Japan, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁶Ueno Touseki Clinic, Fukuoka, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁹Eli Lilly Japan K.K.,, Kobe, Japan, ¹⁰Eli Lilly Japan K.K., Kobe, Japan, ¹¹Div. Rheumatology, Keio University, Tokyo, Japan, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: An all-case post marketing surveillance (PMS) of baricitinib, that started in Sep 2017, collects safety and effectiveness for the first 24 weeks of treatment…
Abstract Number: 1692 • ACR Convergence 2021
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: 3-year Results from the SELECT-EARLY Study
Ronald F van Vollenhoven¹, Tsutomu Takeuchi², Jacob Aelion³, Nilmo Chavez⁴, Pablo Mannucci⁵, Atul Singhal⁶, Jerzy Swierkot⁷, Alan Friedman⁸, Nasser Khan⁸, Yihan Li⁹, Xianwei Bu⁹, Justin Klaff⁸ and Vibeke Strand¹⁰, ¹Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, ⁴Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ⁵Aprillus Asistencia e Investigación, Buenos Aires, Argentina, ⁶Southwest Rheumatology Research LLC, Dallas, TX, ⁷Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., North Chicago, ¹⁰Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy (mono) vs methotrexate (MTX) in MTX-naïve…
Abstract Number: 1709 • ACR Convergence 2021
Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
Min Jung Kim¹, Eun Hye Park² and Kichul Shin³, ¹Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chung-Ang University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].